Source:http://linkedlifedata.com/resource/pubmed/id/12698180
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
8
|
pubmed:dateCreated |
2003-4-16
|
pubmed:abstractText |
The association of endometrial thickness with the risk of developing endometrial cancer (EC) within 2 years was investigated in a consecutive cohort of 1205 breast cancer patients under tamoxifen treatment, undergoing transvaginal ultrasonography (TVUS) for follow-up purpose (asymptomatic, 1068) or for abnormal uterine bleeding (AUB, 137). Linkage with tumour registry allowed for the follow-up of 3184.3 person-years. According to underlying incidence, 1.85 EC cases were expected in the study cohort while 12 were observed (observed/expected ratio=6.49, 95% CI 3.35-11.33; asymptomatic=4.09, 95% CI 1.65-8.43, symptomatic=35.71, 95% CI 11.59-83.34). No EC was observed with thickness (half layer) <3 mm. Raising this threshold increased specificity with a substantial loss of sensitivity (>or=3, >or=4, >or=6, >or=9 mm; spec.=25.8, 44.5, 76.1, 91.5%, sens.=100, 91.6, 75.0, 66.6%). The presence of AUB was rather specific (88.94%) but poorly sensitive (41.67%). A combination of AUB presence/absence and thickness allowed the best accuracy (AUB + thickness >or=3, >or=4 or >or=5; sens.=100, 81.6 or 91.6%; spec.=22.8, 40.4, or 56.7%). Breast cancer patients under tamoxifen might be selected for further invasive assessment on the basis of AUB and endometrial thickness assessed at TVUS.
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/12698180-11720842,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12698180-1972495,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12698180-2197861,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12698180-3860679,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12698180-7755059,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12698180-8116695,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12698180-8133536,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12698180-9369846,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12698180-9400035,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12698180-9809732
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Apr
|
pubmed:issn |
0007-0920
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
22
|
pubmed:volume |
88
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1175-9
|
pubmed:dateRevised |
2009-11-18
|
pubmed:meshHeading |
pubmed-meshheading:12698180-Aged,
pubmed-meshheading:12698180-Antineoplastic Agents, Hormonal,
pubmed-meshheading:12698180-Breast Neoplasms,
pubmed-meshheading:12698180-Endometrial Neoplasms,
pubmed-meshheading:12698180-Female,
pubmed-meshheading:12698180-Humans,
pubmed-meshheading:12698180-Middle Aged,
pubmed-meshheading:12698180-Neoplasm Invasiveness,
pubmed-meshheading:12698180-Neoplasms, Second Primary,
pubmed-meshheading:12698180-Tamoxifen,
pubmed-meshheading:12698180-Ultrasonography,
pubmed-meshheading:12698180-Vagina
|
pubmed:year |
2003
|
pubmed:articleTitle |
Surveillance for endometrial cancer with transvaginal ultrasonography of breast cancer patients under tamoxifen treatment.
|
pubmed:affiliation |
Centro per lo Studio e la Prevenzione Oncologica, Firenze, Italy. s.ciatto@cspo.it
|
pubmed:publicationType |
Journal Article
|